South Korea Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $432 Mn in 2022 to $830 Mn in 2030 with a CAGR of 8.5% for the year 2022-30. The increasing awareness about ADHD in South Korea and rising R&D efforts taken by the pharma companies are the driving factors for the growth of the market. The South Korea ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the key players in the market include Hanmi Pharma, Daewoong Pharma, and Eli Lilly.
The South Korea Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $432 Mn in 2022 and is projected to reach $830 Mn in 2030, exhibiting a CAGR of 8.5% during the forecast period. A record-breaking national budget of $496 Bn has been developed for South Korea for 2022. It established the first additional funding for this year in February, totaling $13 Bn, to assist businesses affected by the pandemic. A large portion of the total, or 35.4%, was given to programs for public health, welfare, and jobs. As the population has aged and the welfare system has been extended, South Korea's government debt-to-GDP ratio has steadily increased, reaching an estimated 49.7% this year from below 40% in 2019 and below 30% in 2010.
In children between the ages of 5 and 15 years, ADHD is one of the most prevalent mental disorders; it impacts 8%-12% of children globally. In terms of monetary costs, stress on families, disruption of academic and professional pursuits, as well as detrimental effects on self-esteem, it has a significant influence on society. Studies conducted in South Korea have linked ADHD to genetic predispositions, exposure to chemicals in the environment, and co-morbidity with other psychiatric illnesses. Despite only being studied in Seoul, the prevalence of ADHD in children was found to range between 5.9% and 9.0%. According to previous studies, the prevalence of adult ADHD in South Korea was estimated to be 2.5%. Childhood ADHD symptoms have been found to persist into adulthood at a rate of about 50%. Nevertheless, symptom domain-specific declining patterns in symptom severity vary. Contrary to how early in childhood hyperactivity and impulsivity improve, the period and rate of improvement in inattention symptoms show later and improve at a slower rate.
Patients who were diagnosed with ADHD as children or adolescents can continue receiving regular therapy as adults, per the current clinical practice in South Korea. Many adult ADHD patients are treated by general practitioners after having ceased receiving treatment following their initial diagnosis in childhood or adolescence and starting it again years later. They also take care of patients who need treatment as adults but did not receive the proper help when it was needed. The risk of adverse outcomes in mental and physical health due to ADHD may be decreased with early and sufficient intervention. Non-pharmacological, pharmacological, or a mix of the two are all possible treatment modalities. The first entails psychosocial, cognitive, and behavioral training that energizes neuropsychological domains linked to ADHD, such as executive and cognitive processes.
In general, stimulants outperform other medications in terms of effectiveness across all age groups. Amphetamines among the stimulants have demonstrated larger impact sizes in reducing the symptoms of ADHD than methylphenidate. Although their mechanisms of action are somewhat different, methylphenidate and amphetamines both have effects that increase the availability of dopamine and norepinephrine in the synaptic cleft, resulting in improved neurotransmission. Methylphenidate's pharmacological action is primarily caused by its blocking of the dopamine and norepinephrine transporters (DAT and NET, respectively), which prevents these neurotransmitters from being taken up again by presynaptic neurons.
Market Growth Drivers
In South Korea, there is a rising consciousness of ADHD, which has increased the number of diagnoses. There is a corresponding rise in demand for ADHD medications as more people become conscious of the condition. ADHD is now more easily recognized in both children and adults as a result of improved diagnostic methods and instruments. As a consequence, diagnoses are now more precise, and the demand for ADHD medications has increased. Major pharmaceutical firms are making significant investments in research and development as a result of realizing the market potential for ADHD in South Korea. New treatments and medicines have been made available as a result, spurring the South Korea ADHD therapeutics market expansion.
Market Restraints
Despite increased awareness of the condition, South Korea still has some societal stigma associated with it. This could discourage some individuals from getting treatment and restrict the South Korea ADHD therapeutics market expansion. The South Korean government is aggressively attempting to reduce healthcare expenses, which could put pressure on the cost of ADHD medications. This may reduce pharmaceutical firms' profitability and slow market expansion. Pharmaceutical companies are expected to become more competitive as the ADHD market in South Korea expands. This might result in reduced prices and profit margins, which might slow market expansion.
Key Players
The safety and effectiveness of medicines and medical equipment in Korea are regulated by the Ministry of Food and Drug Safety (MFDS), formerly the Korea Food & Drug Administration (KFDA). There are five divisions in the MFDS. The two departments in charge of overseeing pharmaceutical and medical device regulations are the Pharmaceutical Safety Bureau and the Medical Device Safety Bureau. For the purpose of ensuring the safety of food and drugs, the MFDS is in charge of developing and implementing policies and laws. Its responsibilities include carrying out safety assessments, establishing safety requirements, carrying out inspections and investigations, giving licenses and permits, and enforcing rules. In order to react to public health emergencies and outbreaks, the MFDS coordinates closely with other governmental organizations, such as the Korea Centres for Disease Control and Prevention (KCDC). In order to promote global food safety and share information on best practices, it also works with international organizations like the World Health Organization (WHO) and the Food and Agriculture Organization (FAO).
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drug Type (Revenue, USD Billion):
By Age Group (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
By Psychotherapy (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.